Medical Organizations Don’t Support Legal Marijuana
DFCR President Dr. Bryon Adinoff discusses the impact of prohibition, how cannabis legalization helps, and the medical community's role.READ MORE
Core to our advocacy efforts, DFCR is proactive in guiding the narrative of cannabis legalization, providing commentary on regulations early in the electoral, legislative, and regulatory process with a focus on offering science-based recommendations to support public health. A critical component of these efforts is engaging medical professionals to expand the endorsement for legalization and regulation by medical organizations and developing partnerships with other organizations, both in the U.S. and internationally, committed to cannabis legalization and regulation.
We ensure that the unique voices of physicians and other medical professionals are at the forefront of the conversation.
We research and track ballot initiatives and legislative initiatives around the country, so we can guide the narrative and provide commentary on regulations early in the process.EXPERT TESTIMONY
We develop partnerships with other organizations that share our values and goals to collaboratively advance our global efforts.
U.S. Federal Legislation to Ensure State’s Rights for Primacy Over Cannabis Regulations and to Decriminalize and Deschedule Cannabis. As of September 2021, the primary bills being considered are the Marijuana Opportunity and Expungement Act (MORE act) in the House and the Cannabis Administration and Opportunity Act (CAOA) in the Senate.
DFCR Experts Testimony to State Legislatures in New Jersey, Delaware, New York, Virginia, Connecticut, Alabama, Kansas and Colorado in Support of Adult Use and Medical Cannabis.
Dr. Deondra Asike provided her first written testimony as DFCR's new Maryland Spokesperson to the House Economic Matters Committee of the Maryland General Assembly in support of HB556 but suggesting several amendments which would further protect patient and consumer safety.READ MORE
Dr. Adinoff's written testimony on a Maryland bill that would cap THC at 15% in the adult-use market and would prevent individuals with a diagnosis of cannabis-induced psychosis from purchasing cannabis in either the medical or adult-use markets.READ MORE